Last $0.57 USD
Change Today -0.0023 / -0.40%
Volume 29.9K
ECTE On Other Exchanges
As of 8:10 PM 10/29/14 All times are local (Market data is delayed by at least 15 minutes).

echo therapeutics inc (ECTE) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/26/13 - $4.91
52 Week Low
09/24/14 - $0.39
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ECHO THERAPEUTICS INC (ECTE)

Related News

No related news articles were found.

echo therapeutics inc (ECTE) Related Businessweek News

No Related Businessweek News Found

echo therapeutics inc (ECTE) Details

Echo Therapeutics, Inc. is engaged in the development of transdermal skin permeation and diagnostic medical devices. It is developing Symphony CGM system (Symphony), a needle-free wireless continuous glucose monitoring system for use in hospital critical care units; and Symphony SkinPrep system, a component of its Symphony for enhanced skin permeation that enables extraction of analytes, such as glucose. The company is also engaged in the development Durhalieve, an AzoneTS formulation of triamcinolone acetonide that has completed Phase III clinical trials for the treatment of corticosteroid-responsive dermatoses. It has a licensing agreement with Ferndale Pharma Group, Inc. to develop, market, sell, and distribute Prelude SkinPrep system for skin preparation prior to the application of topical anesthetics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community; a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell Symphony for continuous glucose monitoring for use by medical facilities and/or individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd. The company was founded in 1989 and is headquartered in Philadelphia, Pennsylvania.

28 Employees
Last Reported Date: 03/28/14
Founded in 1989

echo therapeutics inc (ECTE) Top Compensated Officers

Acting Chief Executive Officer, Chief Complia...
Total Annual Compensation: $220.0K
Compensation as of Fiscal Year 2013.

echo therapeutics inc (ECTE) Key Developments

Echo Therapeutics Hires PricewaterhouseCoopers LLP To Consider Strategic Options

Echo Therapeutics, Inc. (NasdaqCM:ECTE) is exploring financial and strategic alternatives that could sufficiently address its liquidity needs and allow it to resume operations. Such financial and strategic alternatives could include, but are not limited to, a sale of intellectual property and other assets, a merger, other business combination, a capital transaction and/or a voluntary petition for reorganization or liquidation pursuant to the U.S. Bankruptcy Code. Echo Therapeutics has retained PricewaterhouseCoopers LLP's Restructuring and Recovery Services Practice as a financial and restructuring consultant.

Echo Therapeutics, Inc. - Shareholder/Analyst Call

To discuss recent developments and also their goals to establish a new strategic direction for the company which will require the removal of the three predecessor directors for cause

Kimberly A. Burke to Resign as Acting-CEO of Echo Therapeutics

Kimberly A. Burke, the acting-CEO of Echo Therapeutics, has informed the company of her decision to resign. Burke, the company's senior vice president, general counsel and chief compliance officer, was named acting-CEO in June after Echo's contract with its previous acting-CEO, Robert Doman, was not renewed. Doman lost his seat on the company's board of directors in a proxy battle with Platinum Management, Echo's larger stockholder. Burke first joined Echo as a vice president and corporate counsel in 2008.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECTE:US $0.57 USD -0.0023

ECTE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.74 USD +0.24
Bayer AG €108.70 EUR +0.90
Johnson & Johnson $105.56 USD +0.77
Roche Holding AG SFr.280.80 CHF +0.70
View Industry Companies

Industry Analysis


Industry Average

Valuation ECTE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 332.4x
Price/Book 0.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 149.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECHO THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at